Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582137 · ClinicalTrials.gov registry record · Phase 2
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT03582137 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 74 participants.
The verdict
NCT03582137, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD. The study has been powered to detect a clinically significant reduction in Movement Disorder Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores. This is a 1:1 parallel, double-blind, randomized controlled trial (RCT) with 60 participants. The investigators will be recruiting up to 75 participants; the goal is to have 60 participants (30 in CBD group and 30 in placebo group) complete the study. The study drug is obtained from the National Institute on Drug Abuse (NIDA).
Interventions
- OTHER Placebo
- DRUG Cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2022-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03582137
The ClinicalTrials.gov registry entry for NCT03582137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03582137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03582137 about?
NCT03582137 is a clinical study titled "A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease". The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD. The study has been powered to detect a clinically significant reduction...
What is the current status of trial NCT03582137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2018-09-05. Estimated completion is 2022-01-04.
What interventions are being tested in trial NCT03582137?
The interventions under investigation include: Placebo (OTHER), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03582137?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.